Vivani Medical Inc
NASDAQ:VANI

Watchlist Manager
Vivani Medical Inc Logo
Vivani Medical Inc
NASDAQ:VANI
Watchlist
Price: 1.34 USD 0.75% Market Closed
Market Cap: 74m USD
Have any thoughts about
Vivani Medical Inc?
Write Note

Vivani Medical Inc
Total Equity

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Vivani Medical Inc
Total Equity Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Total Equity CAGR 3Y CAGR 5Y CAGR 10Y
Vivani Medical Inc
NASDAQ:VANI
Total Equity
$23.8m
CAGR 3-Years
-31%
CAGR 5-Years
2%
CAGR 10-Years
N/A
Becton Dickinson and Co
NYSE:BDX
Total Equity
$25.9B
CAGR 3-Years
3%
CAGR 5-Years
4%
CAGR 10-Years
18%
Boston Scientific Corp
NYSE:BSX
Total Equity
$20.7B
CAGR 3-Years
8%
CAGR 5-Years
16%
CAGR 10-Years
12%
Stryker Corp
NYSE:SYK
Total Equity
$20.1B
CAGR 3-Years
12%
CAGR 5-Years
10%
CAGR 10-Years
9%
Abbott Laboratories
NYSE:ABT
Total Equity
$39.3B
CAGR 3-Years
5%
CAGR 5-Years
4%
CAGR 10-Years
6%
Intuitive Surgical Inc
NASDAQ:ISRG
Total Equity
$15.6B
CAGR 3-Years
11%
CAGR 5-Years
15%
CAGR 10-Years
18%
No Stocks Found

Vivani Medical Inc
Glance View

Market Cap
74m USD
Industry
Health Care

Vivani Medical Inc is a US-based company operating in Health Care Equipment & Supplies industry. The company is headquartered in Emeryville, California and currently employs 15 full-time employees. The company went IPO on 2014-11-19. Vivani Medical, Inc., formerly Second Sight Medical Products, Inc., is a developer of implantable visual prosthetics that creates an artificial form of useful vision for blind individuals. The firm is the combination of Nano Precision Medical, Inc. (NPM) and Second Sight Medical Products, Inc. NPM is a biopharmaceutical business that develops miniaturized, subdermal drug implants utilizing its NanoPortal technology to enable long-term, near constant-rate delivery of medicines to treat chronic diseases. Its divisions include Drug Implant & Visual Protheses division. The firm's Drug Implant division is developing a portfolio of miniature drug implants which utilize its NanoPortal drug implant technology. Its lead product, NPM-119, is a GLP-1 receptor agonist under development to treat patients with type two diabetes. The firm's Visual Protheses division is developing implantable visual prostheses devices that are intended to deliver useful artificial vision to blind individuals.

VANI Intrinsic Value
0.45 USD
Overvaluation 66%
Intrinsic Value
Price

See Also

What is Vivani Medical Inc's Total Equity?
Total Equity
23.8m USD

Based on the financial report for Jun 30, 2024, Vivani Medical Inc's Total Equity amounts to 23.8m USD.

What is Vivani Medical Inc's Total Equity growth rate?
Total Equity CAGR 5Y
2%

Over the last year, the Total Equity growth was -26%. The average annual Total Equity growth rates for Vivani Medical Inc have been -31% over the past three years , 2% over the past five years .

Back to Top